Aribio has received a $60 million advance payment from China's Puxing Pharmaceutical as part of a global licensing agreement for the Alzheimer's treatment candidate AR1001, signaling an acceleration in commercialization efforts. The company plans to use the funds to finalize global Phase 3 trials, analyze data, establish global approval strategies, and prepare for production and quality control.
On July 13, Aribio announced that it had received an additional $50 million (approximately 75.2 billion won) from Puxing Pharmaceutical, bringing the total option payment to $60 million, which includes an initial $10 million received in May.
This advance payment is part of the exclusive global licensing agreement for AR1001 signed by both companies in May, which has a total contract value of $4.7 billion (approximately 7 trillion won). If Puxing exercises its option for global rights, Aribio will receive additional contract payments, development, approval, and sales milestone payments, as well as royalties on sales.
Recently, the company completed dosing of the last patient in the global Phase 3 trial, POLARIS-AD. This trial involved 1,535 early Alzheimer's patients across 230 institutions in 13 countries, including South Korea, the United States, Canada, Europe, and China. The company is currently in the process of locking the database and conducting statistical analyses, with top-line results expected to be released this fall.
The collaboration between the two companies is expanding beyond technology transfer into a strategic partnership. Puxing has also signed a separate strategic equity investment agreement worth $27.5 million (approximately 42.5 billion won).
Jae-jun Jeong, CEO of Aribio, stated, "The full execution of the advance payment according to the planned procedures demonstrates Puxing's confidence in the clinical success potential and global commercial value of AR1001. As we approach the Phase 3 top-line announcement, we will continue to collaborate to provide new treatment opportunities for Alzheimer's patients worldwide."
Market analysts believe that Aribio's decision on whether to apply for New Drug Application (NDA) approval from the U.S. Food and Drug Administration (FDA) in early 2027, following the Phase 3 results expected in September, will be a critical turning point for the company's value.
Meanwhile, the cumulative contract value of technology exports from domestic pharmaceutical and biotech companies in the first half of the year has reached 13 trillion won, raising expectations that it will surpass last year's record high. Notably, Aribio has achieved results exceeding half of the domestic biotech industry's technology export volume in just the first half of this year.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.